Genetic Structures Commons^™

Systematic Evaluation Of Batch Effects In The Cancer Genome Atlas Program Underscores The Need For Batch-Controlled Analysis, Zhongxuan Chen, Stepan Nersisyan, Isidore Rigoutsos, Eric Londin

Alpha Omega Alpha Research Symposium Posters

Purpose: To systematically assess the impact of batch effects on differential expression of isomiR, mRNA, and non-coding RNA (sncRNA) across 13 The Cancer Genome Atlas (TCGA) cancer types and develop a standardized, batch-controlled analysis protocol for TCGA datasets.

Methods: Data analysis and visualization were performed using Python v3.12. Plots were generated using matplotlib and seaborn. isomiR, mRNA, and sncRNA sequences across 13 TCGA cancer types were used. Principal Component Analysis (PCA) was performed using scikit-learn for dimensionality reduction. Differential expression was conducted using DESeq2 under the following protocols: 1) primary tumor samples vs matched normal samples processed in the same …

Redesigning Beauty: Promoting Universal Design For Upper Extremity Deficits, Sierra Louise Forkey, Cynthia Haynes

Fall 2025 OTD Capstone Symposium

The purpose of this capstone project is to research and identify barriers individuals with upper extremity deficits face when participating in personal hygiene and grooming tasks and to use this information to advocate for individuals with upper extremity deficits by promoting inclusive design, educating consumers, and informing beauty manufacturers on the importance of implementing a universal design component to allow products to be more accessible.

Investigating The Drug Response Of Pdac Cells To Pan-Kras Inhibitor, Jalyn De La Fuente, Yi Xu, Jun Liu, Angel Dominquez, Ava Sanchez, Pei Wang

Posters - 2025

Pancreatic ductal adenocarcinoma (PDAC) is an exocrine pancreatic cancer. It is one of the most lethal types of cancer and is projected to become the second leading cause of cancer-related deaths by 20401 . One major challenge in treating PDAC is drug resistance and the lack of effective treatments. Oncogenic KRAS mutation and loss of function mutation in tumor suppressor genes including P16, TP53, and SMAD4 are found in most PDAC patients. It is unclear whether the different driver mutations can affect the tumor responses to chemo- and targeted therapy. Gemcitabine, a chemotherapy drug, is a cytotoxic agent that has …